Search Results - "van der Sangen, Niels M. R."

Patient-tailored antithrombotic therapy following percutaneous coronary intervention by van der Sangen, Niels M R, Rozemeijer, Rik, Chan Pin Yin, Dean R P P, Valgimigli, Marco, Windecker, Stephan, James, Stefan K, Buccheri, Sergio, ten Berg, Jurriën M, Henriques, José P S, Voskuil, Michiel, Kikkert, Wouter J

“…Abstract Dual antiplatelet therapy has long been the standard of care in preventing coronary and cerebrovascular thrombotic events in patients with chronic…”
Get full text

Worsening Renal Function After Acute Myocardial Infarction: A Bad Omen? by van der Sangen, Niels M.R., Claessen, Bimmer E.P.M.

“…Importantly, 177 patients who were rehospitalized for heart failure in the first year of follow-up were excluded from this study. Because of the observational…”
Get full text

Sex differences in body composition in people with prediabetes and type 2 diabetes as compared with people with normal glucose metabolism: the Maastricht Study by de Ritter, Rianneke, Sep, Simone J. S., van Greevenbroek, Marleen M. J., Kusters, Yvo H. A. M., Vos, Rimke C., Bots, Michiel L., Kooi, M. Eline, Dagnelie, Pieter C., Eussen, Simone J. P. M., Schram, Miranda T., Koster, Annemarie, Brouwers, Martijn C. G., van der Sangen, Niels M. R., Peters, Sanne A. E., van der Kallen, Carla J. H., Stehouwer, Coen D. A.

“…Aims/hypothesis Obesity is a major risk factor for type 2 diabetes. However, body composition differs between women and men. In this study we investigate the…”
Get full text

Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients: Rationale and Design of the LEGACY study by van der Sangen, Niels M.R., Küçük, I. Tarik, Sivanesan, Shabiga, Appelman, Yolande, ten Berg, Jurriën M., Verburg, Ashley, Azzahhafi, Jaouad, Arkenbout, E. Karin, Kikkert, Wouter J., Pisters, Ron, Jukema, J. Wouter, Arslan, Fatih, van ‘t Hof, Arnoud, Ilhan, Mustafa, Hoebers, Loes P., van der Schaaf, René J., Damman, Peter, Woudstra, Pier, van de Hoef, Tim P., Bax, Matthijs, Anthonio, Rutger L., Polad, Jawed, Adriaenssens, Tom, Dewilde, Willem, Zivelonghi, Carlo, Laanmets, Peep, Majas, Risko, Dijkgraaf, Marcel G.W., Claessen, Bimmer E.P.M., Henriques, José P.S.

“…Early aspirin withdrawal, also known as P2Y12-inhibitor monotherapy, following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute…”
Get full text

Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities by van Veelen, Anna, van der Sangen, Niels M R, Delewi, Ronak, Beijk, Marcel A M, Henriques, Jose P S, Claessen, Bimmer E P M

“…Acute coronary syndrome (ACS) mostly arises from so-called vulnerable coronary plaques, particularly prone for rupture. Vulnerable plaques comprise a specific…”
Get full text

External validation of the GRACE risk score and the risk–treatment paradox in patients with acute coronary syndrome by van der Sangen, Niels M R, Azzahhafi, Jaouad, Chan Pin Yin, Dean R P P, Peper, Joyce, Rayhi, Senna, Walhout, Ronald J, Tjon Joe Gin, Melvyn, Nicastia, Deborah M, Langerveld, Jorina, Vlachojannis, Georgios J, van Bommel, Rutger J, Appelman, Yolande, Henriques, José P S, ten Berg, Jurriën M, Kikkert, Wouter J

“…ObjectivesTo validate the Global Registry of Acute Coronary Events (GRACE) risk score and examine the extent and impact of the risk–treatment paradox in…”
Get full text

Impact of recurrent ischaemic and bleeding events on quality of life in patients with acute coronary syndrome: Insights from the FORCE-ACS registry by van der Sangen, Niels M R, Azzahhafi, Jaouad, Chan Pin Yin, Dean R P P, Rayhi, Senna, van Weede, Victoria M, Walhout, Ronald J, Tjon Joe Gin, Melvyn, Pisters, Ron, Nicastia, Deborah M, Langerveld, Jorina, Vlachojannis, Georgios J, van Bommel, Rutger J, Appelman, Yolande, Henriques, José P S, ten Berg, Jurriën M, Kikkert, Wouter J

“…ObjectivePatients with acute coronary syndrome (ACS) remain at high risk for recurrent ischaemic and bleeding events during follow-up. Our study aimed to…”
Get full text

Cangrelor Use in Routine Practice: A Two-Center Experience by van der Sangen, Niels M R, Cheung, Ho Yee, Verouden, Niels J W, Appelman, Yolande, Beijk, Marcel A M, Claessen, Bimmer E P M, Delewi, Ronak, Knaapen, Paul, Lemkes, Jorrit S, Nap, Alexander, Vis, M Marije, Kikkert, Wouter J, Henriques, José P S

“…Cangrelor is the first and only intravenous P2Y -inhibitor and is indicated when (timely) administration of an oral P2Y inhibitor is not feasible in patients…”
Get full text

Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards “Personalized Medicine” in Daily Clinical Practice by Chan Pin Yin, Dean R. P. P., Vos, Gert-Jan A., van der Sangen, Niels M. R., Walhout, Ronald, Tjon Joe Gin, R. Melvyn, Nicastia, Deborah M., Langerveld, Jorina, Claassens, Daniël M. F., Gimbel, Marieke E., Azzahhafi, Jaouad, Bor, Willem L., Oirbans, Tom, Dekker, Johan, Vlachojannis, Georgios J., van Bommel, Rutger J., Appelman, Yolande, Henriques, José P. S., Kikkert, Wouter J., ten Berg, Jurriën M.

“…Diagnostic and treatment strategies for acute coronary syndrome have improved dramatically over the past few decades, but mortality and recurrent myocardial…”
Get full text

Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study by van der Sangen, Niels M R, Claessen, Bimmer E P M, Küçük, I Tarik, den Hartog, Alexander W, Baan, Jan, Beijk, Marcel A M, Delewi, Ronak, van de Hoef, Tim P, Knaapen, Paul, Lemkes, Jorrit S, Marques, Koen M, Nap, Alexander, Verouden, Niels J W, Vis, M Marije, de Winter, Robbert J, Kikkert, Wouter J, Appelman, Yolande, Henriques, Jose P S

“…Early P2Y inhibitor monotherapy has emerged as a promising alternative to 12 months of dual antiplatelet therapy following percutaneous coronary intervention…”
Get full text

Identification and treatment of the vulnerable coronary plaque by van Veelen, Anna, van der Sangen, Niels M R, Henriques, José P S, Claessen, Bimmer E P M

“…Acute coronary syndrome mostly arises from rupture or erosion of a vulnerable plaque. Vulnerable plaques typically appear as lipid-rich plaques with a thin…”
Get full text

Data quality within the Netherlands Heart Registration: Ready for prime time? by van der Sangen, Niels M. R., Henriques, José P. S.

“…[...]all four clinical outcome measures collected in the NHR PCI registry [i.e. coronary bypass grafting within 24 h, myocardial infarction (MI) within 30…”
Get full text

Reduction in Junctophilin 2 Expression in Cardiac Nodal Tissue Results in Intracellular Calcium-Driven Increase in Nodal Cell Automaticity by Landstrom, Andrew P., Yang, Qixin, Sun, Bo, Perelli, Robin M., Bidzimou, Minu-Tshyeto, Zhang, Zhushan, Aguilar-Sanchez, Yuriana, Alsina, Katherina M., Cao, Shuyi, Reynolds, Julia O., Word, Tarah A., van der Sangen, Niels M.R., Wells, Quinn, Kannankeril, Prince J., Ludwig, Andreas, Kim, Jeffrey J., Wehrens, Xander H.T.

“…Spontaneously depolarizing nodal cells comprise the pacemaker of the heart. Intracellular calcium (Ca ) plays a critical role in mediating nodal cell…”
Get full text

Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients by Azzahhafi, Jaouad, van den Broek, Wout W.A., Chan Pin Yin, Dean R.P.P., van der Sangen, Niels M.R., Sivanesan, Shabiga, Bofarid, Salahodin, Peper, Joyce, Claassens, Daniel M.F., Janssen, Paul W.A., Harmsze, Ankie M., Walhout, Ronald J., Tjon Joe Gin, Melvyn, Nicastia, Deborah M., Langerveld, Jorina, Vlachojannis, Georgios J., van Bommel, Rutger J., Appelman, Yolande, van Schaik, Ron H.N., Henriques, José P.S., Kikkert, Wouter J., ten Berg, Jurriën M.

“…CYP2C19 genotype-guided de-escalation from ticagrelor or prasugrel to clopidogrel may optimize the balance between ischemic and bleeding risk in patients with…”
Get full text

XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: ‘The New Normal’? by Sangen, Niels MR van der, Kikkert, Wouter J, Henriques, José PS, Claessen, Bimmer EPM

Get full text

Outcomes of newly diagnosed atrial fibrillation in patients with acute coronary syndromes by Bor, Willem Lambertus (Wilbert), Azzahhafi, Jaouad, Maio, Nino di, van der Sangen, Niels M.R., Verburg, Ashley, Rayhi, Senna, Peper, Joyce, Chan Pin Yin, Dean R.P.P., ten Berg, Jurrien M.

Get full text

Cost-effectiveness of Implementing a Genotype-Guided De-Escalation Strategy in Patients with Acute Coronary Syndrome by van den Broek, W W A, Azzahhafi, Jaouad, Chan Pin Yin, Dean R P P, van der Sangen, Niels M R, Sivanesan, Shabiga, Dijksman, Lea M, Walhout, Ronald J, Gin, Melvyn Tjon Joe, Breet, Nicoline J, Langerveld, Jorina, Vlachojannis, Georgios J, van Bommel, Rutger J, Appelman, Yolande, van Schaik, Ron H N, Henriques, José P S, Kikkert, Wouter J, ten Berg, Jurriën M

“…Abstract Aims A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function…”
Get full text

One-year follow-up of patients treated with single antiplatelet therapy directly after percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome by van der Sangen, Niels M.R, Claessen, Bimmer E.P.M, Kucuk, I. Tarik, Hartog, Alexander W. den, Kikkert, Wouter J, Appelman, Yolande, Henriques, Jose P.S

“…Graphical Abstract Clinical outcomes and treatment adherence during 12 months follow-up. *Second bleeding event in same patient. PCI, percutaneous coronary…”
Get full text

Real-World Implementation of a Genotype-Guided P2Y 12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients by Azzahhafi, Jaouad, van den Broek, Wout W A, Chan Pin Yin, Dean R P P, van der Sangen, Niels M R, Sivanesan, Shabiga, Bofarid, Salahodin, Peper, Joyce, Claassens, Daniel M F, Janssen, Paul W A, Harmsze, Ankie M, Walhout, Ronald J, Tjon Joe Gin, Melvyn, Nicastia, Deborah M, Langerveld, Jorina, Vlachojannis, Georgios J, van Bommel, Rutger J, Appelman, Yolande, van Schaik, Ron H N, Henriques, José P S, Kikkert, Wouter J, Ten Berg, Jurriën M

“…CYP2C19 genotype-guided de-escalation from ticagrelor or prasugrel to clopidogrel may optimize the balance between ischemic and bleeding risk in patients with…”
Get full text

Outcomes of newly diagnosed atrial fibrillation in patients with acute coronary syndromes by Bor, Willem Lambertus Wilbert, Azzahhafi, Jaouad, Maio, Nino di, van der Sangen, Niels M R, Verburg, Ashley, Rayhi, Senna, Peper, Joyce, Chan Pin Yin, Dean R P P, Ten Berg, Jurrien M

“…Acute coronary syndrome (ACS) is frequently accompanied by newly diagnosed atrial fibrillation (AF). We aimed to compare the risk of major adverse…”
Get more information